Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.8209
-0.1084 (-11.66%)
At close: Jun 27, 2025, 4:00 PM
0.8260
+0.0051 (0.62%)
After-hours: Jun 27, 2025, 7:54 PM EDT
Lexicon Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Lexicon Pharmaceuticals stock ranges from a low of $1.00 to a high of $6.00. The average analyst price target of $3.67 forecasts a 347.07% increase in the stock price over the next year.
Price Target: $3.67 (+347.07%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +387.27% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +387.27% | Mar 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +630.91% | Mar 7, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +387.27% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
17.37M
from 31.08M
Decreased by -44.11%
Revenue Next Year
12.72M
from 17.37M
Decreased by -26.80%
EPS This Year
-0.40
from -0.63
EPS Next Year
-0.36
from -0.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 53.3M | 28.9M | 71.3M | ||
| Avg | 17.4M | 12.7M | 49.6M | ||
| Low | 1.2M | 5.7M | 28.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.6% | 66.2% | 460.6% | ||
| Avg | -44.1% | -26.8% | 290.0% | ||
| Low | -96.0% | -67.2% | 126.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.24 | -0.21 | -0.11 | ||
| Avg | -0.40 | -0.36 | -0.22 | ||
| Low | -0.63 | -0.52 | -0.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.